Lupus & antiphospholipid syndrome
Comparative Performance of SLECRISK and PREVENT for Cardiovascular Risk Prediction in Systemic Lupus Erythematosus
Authors' conclusion
Although overall discrimination was similar, SLECRISK demonstrated better agreement between predicted and observed CV events and higher sensitivity for identifying patients who developed MACE.
Study context
- Population
- Adults with systemic lupus erythematosus (SLE) meeting ACR 1997 and/or EULAR criteria
- Participants
- 1,243 adults
- Comparison
- SLECRISK vs PREVENT for prediction of 10-year risk of MI, stroke or cardiac death
- Outcome
- Discrimination for 10-year risk of MI, stroke or cardiac death
- Follow-up
- 10 years
Methodological detailsSLE cohort, comparison of two cardiovascular (CV) risk prediction models
- SLE cohort
- Comparison of two CV risk prediction models
Performance
As reported in the abstract
Discrimination (AUC)
| Test or model | AUC |
|---|---|
| SLECRISK | 0.74 |
| PREVENT | 0.76 |
AUC
SLECRISK0.74
PREVENT0.76
- SLECRISK vs PREVENT: P = 0.64 — similar discrimination
Further findings
| Outcome | SLECRISK | PREVENT | P value |
|---|---|---|---|
| Sensitivity for 10-year MACE at 7.5% predicted-risk threshold | |||
| Sensitivity | 0.74 | 0.29 | |
| Characteristics: classified by SLECRISK alone vs PREVENT only or bothSLECRISK only vs PREVENT only or both | mean 42.5 years | P < 0.001 | |
| Systolic BP (mmHg) | 122.0 | — not stated in the abstract | |
| Creatinine (mg/dL) | 0.91 | — not stated in the abstract | |
| anti-dsDNA | 85.7% | — not stated in the abstract | |
| anti-RNP | 56.1% | — not stated in the abstract | |
| Characteristics: classified by SLECRISK alone vs PREVENT only or bothSLECRISK only vs PREVENT only or both | P < 0.001 | ||
| Characteristics: classified by SLECRISK alone vs PREVENT only or bothSLECRISK only vs PREVENT only or both | P < 0.001 |
— not stated in the abstract
- Characteristics: classified by SLECRISK alone vs PREVENT only or both: PREVENT only or both mean 57.2 years · systolic BP (mmHg) 145.0 · creatinine (mg/dL) 2.63 · anti-dsDNA 73.6% · anti-RNP 28.6%
Sensitivity for 10-year major adverse CV events (MACE) at 7.5% predicted-risk threshold
- SLECRISK identified more patients who subsequently developed MACE
Classified as moderate/high risk by either model
- Moderate/high risk by either model
- 581 (46.7%)
- By SLECRISK only
- 490
- By PREVENT only or by both
- 91
Original publication
Comparative Performance of SLECRISK and PREVENT for Cardiovascular Risk Prediction in Systemic Lupus Erythematosus. J Rheumatol. Published 1 August 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →